Johnson & Johnson Family of Companies
NEWS
Novartis filed a federal lawsuit against a former executive, Alisha Alaimo. The lawsuit alleged that Alaimo stole confidential files using a flash drive before joining Biogen.
According to HBM Partners, a healthcare investing firm, out of the drugs approved over the last five years, 63 percent originated at smaller companies.
Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.
Shares of Protagonist Therapeutics plunged more than 60 percent in pre-market trading after the company announced it will discontinue its Phase IIb ulcerative colitis treatment after a review from an Independent Data Monitoring Committee (DMC).
The FDA granted a Priority Review designation to Pfizer and partner Astellas Pharma for expanded use of Xtandi in prostate cancer treatment.
Platinum Equity submitted a binding offer to Johnson & Johnson to buy LifeScan for $2.1 billion.
The Wall Street Journal speculated today that it won’t be long before drug manufacturers start consolidating in order to improve their bottom lines.
Aldeyra Therapeutics has signed a collaboration research deal with Janssen Research & Development, a Johnson & Johnson company.
Eli Lilly and Company published results from a new Phase IIIb clinical trial of Trulicity (dulaglutide) in combination with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, which has shown improved blood sugar control in adults with type 2 diabetes.
JOBS
IN THE PRESS